ENIGM

• Research type

  Research Study

• Full title

  Edinburgh Myeloma Genome Initiative

• IRAS ID

  329233

• Contact name

  Aneta Mikulasova

• Contact email

  amikulas@ed.ac.uk

• Sponsor organisation

  University of Edinburgh

• Duration of Study in the UK

  0 years, 11 months, 31 days

• Research summary

  Our research, the "Edinburgh Myeloma Genome Initiative," is focused on a blood cancer known as multiple myeloma. We aim to understand why it affects people differently and how we can better diagnose and treat it. By exploring the genetic factors of this cancer, we are looking into how certain genetic changes can affect how the cancer grows and responds to treatments. This research is important because it could transform how we manage and treat multiple myeloma. By understanding the disease's genetic aspects, doctors could tailor treatment plans to each patient's specific needs, potentially leading to better health outcomes.

  Individuals diagnosed with multiple myeloma are invited to participate. Patients will be recruited from Freeman Hospital (Newcastle Hospitals NHS Foundation Trust), and the research will be conducted at Newcastle University. These venues combine clinical expertise with advanced research facilities.
  In this study, during regular diagnostic procedures, we will collect additional bone marrow and blood samples without requiring extra needle pricks. These samples, along with updates on participants' health and treatment experiences, are vital for our genetic research. There are no extra hospital visits or special procedures. Using advanced technology, we will examine the genetic information in the samples, seeking patterns or markers associated with the disease. This study does not involve testing new drugs or treatments. It will not change the current participants’ clinical care, but their contributions could lead to significant advancements in understanding and treating multiple myeloma in the future.

  We adhere to strict ethical guidelines to ensure patient safety and data privacy throughout the study. Participants can be assured of the highest standards of ethical conduct and confidentiality.

• REC name

  London - South East Research Ethics Committee

• REC reference

  24/LO/0682

• Date of REC Opinion

  16 Dec 2024

• REC opinion

  Further Information Favourable Opinion